trending Market Intelligence /marketintelligence/en/news-insights/trending/fuxpnoleetwvj9b9tk_5zg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck & Co. Q2 profit up YOY; EPS guidance raised

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Merck & Co. Q2 profit up YOY; EPS guidance raised

Merck & Co. Inc., maker of the blockbuster cancer drug Keytruda, said its second-quarter earnings rose year over year, and raised its income guidance for 2018.

The Kenilworth, N.J.-based drugmaker said its second-quarter non-GAAP net income was $2.85 billion, or $1.06 per share, up from $2.78 billion, or $1.01 per share, a year earlier.

The S&P Capital IQ normalized EPS consensus estimate for the second quarter was $1.03.

Total sales for the quarter reached $10.47 billion, up 5% year over year from $9.93 billion.

Pharmaceutical sales for the quarter rose 6% year over year to $9.28 billion, driven by growth in oncology, vaccines and hospital acute care but offset by lower sales in virology and loss of market exclusivity for some products. Second-quarter animal health sales rose 14% year over year to $1.09 billion.

Merck's second-quarter GAAP net income was $1.71 billion, or 63 cents per share, down from $1.95 billion, or 71 cents per share, in the same period last year.

Merck narrowed its revenue outlook range for 2018 to between $42 billion and $42.8 billion, compared to a previous range of $41.8 billion and $43.0 billion.

The drugmaker raised its non-GAAP EPS guidance range for 2018, now targeting between $4.22 and $4.30 compared to $4.16 to $4.28 previously.

The S&P Capital IQ normalized EPS consensus estimate for full-year 2018 is $4.24.

On a GAAP basis, the company expects to post an income of $2.51 per share to $2.59 per share, which is higher than the $2.45 per share to $2.57 per share expected previously.